Faster chemo boosts survival from type of nerve cancer

Posted on Mon, February 25, 2008 at 10:00PM by Registered CommenterNeil Hutchison | Comments13 Comments | References3 References

Celebrex and curcumin

Posted on Sun, February 24, 2008 at 08:15AM by Registered CommenterNeil Hutchison | Comments19 Comments | References36 References

We might have Dr. Durden test this…

Celecoxib (Celebrex) is a worldwide top branded COX-2-specific inhibitor. It was shown to provide relief of arthritic pain and inflammation and has recently been under investigation for the prevention and treatment of cancer. However, recent studies showed that long term use of high doses of celecoxib is associated with an increased cardiovascular toxicity. We discovered that the addition of curcumin, a natural COX-2 inhibitor, to celecoxib synergistically (up to 1000%) augments the growth inhibitory effects of celecoxib in in-vitro and in-vivo models of arthritis and cancer, thus rendering effective action of the drug at up to tenfold lower dose. This may pave the way for a novel strategy to treat arthritis and cancer because its effect can be achieved in the serum of patients receiving standard anti inflammatory or anti-neoplastic dosages of celecoxib, and involves a regimen with a very low profile of side effects. Preliminary data suggest that the combination is not limited only to celecoxib and that addition of curcumin to other NSAIDs such as sulindac, synergistically augments neoplastic cell growth inhibition. Based on these finding we received an IRB approval to evaluate celecoxib+curcumin in patients with osteoarthritis, pancreatic cancer and metastatic CRC.